Products and Services
Innovation in biomedicine
Specialised Inflammasome Services for Pharmaceutical and Biomedical Development
Translational solutions from the laboratory to clinical practice.
Our scientific services accelerate and enhance the studies of pharmaceutical companies, biotechnology companies and research and health institutions to standardise products and services in the field of inflammasome therapies.
Products
Solutions for clinical use
A range for rapid and accurate detection of NLRP3 with a minimal blood sample using a highly sensitive ex vivo immunoassay.
Cutting-edge technology for the precise detection of inflammasome activation in clinical and research settings, and an essential tool for validating NLRP3 targets in the development of anti-inflammatory therapies.
VIVA ELISA® RUO
Research Use Only. Launch Q4 2025. Highly sensitive ELISA kit for basic research and pharmaceutical development.
"Essential tool for validating NLRP3 targets in the development of anti-inflammatory therapies".
VIVA ELISA®
FDA/CE certification planned. Launch 2028. First clinical ELISA for monitoring NLRP3-dependent diseases.
"Revolutionising the management of critically ill patients with immunometabolic dysfunction".
VIVA SEPS CARE®
Automatic random access device for mass use in hospitals and clinical laboratories. Under evaluation
"The next generation in rapid diagnosis of severe sepsis and hyperinflammatory responses".
State of the art in sepsis diagnosis prior to VIVA ELISA®:
- Risk scores: SIRS, SOFA, qSOFA, which identify sepsis with limitations in speed, accuracy and prognostic use.
- Diagnostic tools: such as blood cultures, clinical history and direct observation, of non-specific and complex use, the former are often used in combination on an empirical basis with observation and various markers.
- Procalcitonin (PCT), C-Reactive Protein (CRP), Lactate and IL-6, non-specific and insufficiently accurate.
- Conventional treatment: Antimicrobial therapy, fluid resuscitation, vasopressors and anticoagulants. There may be cases of homogeneous treatment for varying immunocompetence situations.
We work with the medical community to overcome current barriers to sepsis diagnosis, providing greater accuracy, speed and clinical utility with a focus on the innate immune system and complementary to current tools.
Talk to us
Do you have a NLRP3 Related Project?
We are your ideal partner if you need:
- Validate inflammasome modulating compounds.
- Biomarkers for clinical trials in inflammatory diseases.
- Phenotypic characterisation by ASC-Speck.
News
Join the cutting edge of biomedical research
Subscribe to VIVA Insights: The leading newsletter on inflammasomes and sepsis
Receive exclusive analysis, scientific breakthroughs and collaboration opportunities from our network of international partners and benchmarks.
